Barrington Research Downgrade Haemonetics Corporation [HAE]. What else is Wall St. saying?

Haemonetics Corporation [NYSE: HAE] jumped around 11.46 points on Wednesday, while shares priced at $105.91 at the close of the session, up 12.13%. The company report on October 7, 2020 that Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2021 Results: November 4, 2020.

Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednesday, November 4, 2020. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on November 4, 2020.

The call can be accessed with the following information:.

Haemonetics Corporation stock is now -7.82% down from its year-to-date (YTD) trading value. HAE Stock saw the intraday high of $106.97 and lowest of $95.04 per share. The company’s 52-week high price is 130.75, which means current price is +67.02% above from all time high which was touched on 02/05/20.

Compared to the average trading volume of 506.55K shares, HAE reached a trading volume of 1314365 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Haemonetics Corporation [HAE]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HAE shares is $114.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HAE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Barrington Research have made an estimate for Haemonetics Corporation shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on May 06, 2020. The new note on the price target was released on March 31, 2020, representing the official price target for Haemonetics Corporation stock. Previously, the target price had yet another raise to $138, while Needham analysts kept a Buy rating on HAE stock. On August 07, 2019, analysts increased their price target for HAE shares from 116 to 139.

The Average True Range (ATR) for Haemonetics Corporation is set at 3.65, with the Price to Sales ratio for HAE stock in the period of the last 12 months amounting to 5.77. The Price to Book ratio for the last quarter was 8.77, with the Price to Cash per share for the same quarter was set at 5.35. Price to Free Cash Flow for HAE in the course of the last twelve months was 45.79 with Quick ratio for the last quarter at 1.10.

How has HAE stock performed recently?

Haemonetics Corporation [HAE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.14. With this latest performance, HAE shares gained by 25.34% in over the last four-week period, additionally sinking by -7.10% over the last 6 months – not to mention a drop of -14.15% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HAE stock in for the last two-week period is set at 72.09, with the RSI for the last a single of trading hit 76.60, and the three-weeks RSI is set at 68.18 for Haemonetics Corporation [HAE]. The present Moving Average for the last 50 days of trading for this stock 89.42, while it was recorded at 96.33 for the last single week of trading, and 98.18 for the last 200 days.

Haemonetics Corporation [HAE]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Haemonetics Corporation [HAE] shares currently have an operating margin of +19.73 and a Gross Margin at +51.50. Haemonetics Corporation’s Net Margin is presently recorded at +7.74.

Return on Total Capital for HAE is now 19.06, given the latest momentum, and Return on Invested Capital for the company is 7.91. Return on Equity for this stock inclined to 12.20, with Return on Assets sitting at 6.02. When it comes to the capital structure of this company, Haemonetics Corporation [HAE] has a Total Debt to Total Equity ratio set at 75.25. Additionally, HAE Total Debt to Total Capital is recorded at 42.94, with Total Debt to Total Assets ending up at 34.87. Long-Term Debt to Equity for the company is recorded at 60.90, with the Long-Term Debt to Total Capital now at 34.75.

Reflecting on the efficiency of the workforce at the company, Haemonetics Corporation [HAE] managed to generate an average of $25,475 per employee. Receivables Turnover for the company is 5.64 with a Total Asset Turnover recorded at a value of 0.78.Haemonetics Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.90.

Earnings analysis for Haemonetics Corporation [HAE]

With the latest financial reports released by the company, Haemonetics Corporation posted 0.87/share EPS, while the average EPS was predicted by analysts to be reported at 0.69/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 26.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HAE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Haemonetics Corporation go to 12.00%.

Insider trade positions for Haemonetics Corporation [HAE]

There are presently around $5,249 million, or 99.70% of HAE stock, in the hands of institutional investors. The top three institutional holders of HAE stocks are: VANGUARD GROUP INC with ownership of 5,301,013, which is approximately -4.028% of the company’s market cap and around 1.00% of the total institutional ownership; BLACKROCK INC., holding 5,095,602 shares of the stock with an approximate value of $539.67 million in HAE stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $422.37 million in HAE stock with ownership of nearly 37.812% of the company’s market capitalization.

Positions in Haemonetics Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 162 institutional holders increased their position in Haemonetics Corporation [NYSE:HAE] by around 8,634,465 shares. Additionally, 148 investors decreased positions by around 10,213,064 shares, while 25 investors held positions by with 30,715,955 shares. The mentioned changes placed institutional holdings at 49,563,484 shares, according to the latest SEC report filing. HAE stock had 62 new institutional investments in for a total of 1,589,169 shares, while 43 institutional investors sold positions of 3,320,615 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam